NuVasive, Inc.

NasdaqGS:NUVA 株式レポート

時価総額:US$2.1b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

NuVasive 過去の業績

過去 基準チェック /16

NuVasiveの収益は年間平均-33%の割合で減少していますが、 Medical Equipment業界の収益は年間 増加しています。収益は年間8.7% 2.1%割合で 増加しています。 NuVasiveの自己資本利益率は3.2%であり、純利益率は2.3%です。

主要情報

-33.0%

収益成長率

-33.2%

EPS成長率

Medical Equipment 業界の成長8.9%
収益成長率2.1%
株主資本利益率3.2%
ネット・マージン2.3%
前回の決算情報30 Jun 2023

最近の業績更新

Recent updates

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

Apr 18
Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

Jan 24
What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Dec 31
NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

Dec 05
Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Nov 13
These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Sep 22
Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

Sep 01
Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

NuVasive Likely Undervalued, But It's Hard To Find Catalysts

Aug 17

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

Aug 11
Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M

Aug 03

NuVasive: Industry Tailwinds More Than Fairly Priced

Jun 13

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Jun 01
Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

May 11
Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Apr 20
NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

Mar 30
At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

NuVasive's Turnaround Story Needs A Boost From Better Results

Mar 01

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Dec 28
Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?

Dec 02
Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Nov 11
NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate

Oct 21
NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate

Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital

Sep 29
Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital

At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?

Aug 18
At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?

NuVasive Still Getting No Love With COVID-19 And Competitive Worries

Aug 12

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

Jul 27
Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

Are Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?

Jun 17
Are Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?

Some Investors May Be Worried About NuVasive's (NASDAQ:NUVA) Returns On Capital

May 30
Some Investors May Be Worried About NuVasive's (NASDAQ:NUVA) Returns On Capital

Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Is Not Excessive At All

May 12
Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Is Not Excessive At All

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

Mar 30
Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

Is Now The Time To Look At Buying NuVasive, Inc. (NASDAQ:NUVA)?

Mar 09
Is Now The Time To Look At Buying NuVasive, Inc. (NASDAQ:NUVA)?

Need To Know: NuVasive, Inc. (NASDAQ:NUVA) Insiders Have Been Buying Shares

Feb 16
Need To Know: NuVasive, Inc. (NASDAQ:NUVA) Insiders Have Been Buying Shares

A Look At The Fair Value Of NuVasive, Inc. (NASDAQ:NUVA)

Jan 26
A Look At The Fair Value Of NuVasive, Inc. (NASDAQ:NUVA)

NuVasive stock gains on study results of its X360 surgery approach

Jan 06

What Type Of Returns Would NuVasive's(NASDAQ:NUVA) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Jan 05
What Type Of Returns Would NuVasive's(NASDAQ:NUVA) Shareholders Have Earned If They Purchased Their SharesYear Ago?

収支内訳

NuVasive の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGS:NUVA 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 231,22628653102
31 Mar 231,21920650100
31 Dec 221,2024063499
30 Sep 221,199-2063698
30 Jun 221,174-4062898
31 Mar 221,159-3762494
31 Dec 211,139-6461093
30 Sep 211,129-2659489
30 Jun 211,153259486
31 Mar 211,062-5056384
31 Dec 201,051-3754780
30 Sep 201,069-956377
30 Jun 201,065-457075
31 Mar 201,1536159673
31 Dec 191,1686561172
30 Sep 191,1464859370
30 Jun 191,1275258167
31 Mar 191,1164957465
31 Dec 181,1021257662
30 Sep 181,0852456857
30 Jun 181,0604155355
31 Mar 181,0384254653
31 Dec 171,0278254050
30 Sep 171,0276454751
30 Jun 171,0193555450
31 Mar 179965354950
31 Dec 169623753448
30 Sep 169064251044
30 Jun 168675148940
31 Mar 168343146837
31 Dec 158116645736
30 Sep 158006245437
30 Jun 157904745737
31 Mar 157773346038
31 Dec 14762-1745737
30 Sep 14749-1845736
30 Jun 14728-944634
31 Mar 14703-1143332
31 Dec 13685842032
30 Sep 13660-140333
30 Jun 13639-638933
31 Mar 13628337735
31 Dec 12620337235
30 Sep 12605-436834

質の高い収益: NUVAには$16.9M } という大きな 一回限りの 損失があり、過去 12 か月の財務実績が30th June, 2023に影響を及ぼしています。

利益率の向上: NUVA過去に利益を上げました。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: NUVAの収益は過去 5 年間で年間33%減少しました。

成長の加速: NUVAは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。

収益対業界: NUVA昨年収益を上げたため、昨年の収益成長をMedical Equipment業界 ( 2.4% ) と比較することは困難です。


株主資本利益率

高いROE: NUVAの 自己資本利益率 ( 3.2% ) は 低い とみなされます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘